<DOC>
	<DOCNO>NCT00295672</DOCNO>
	<brief_summary>Our aim conduct multicenter phase II trial cisplatin-oral vinorelbine -radiotherapy combination induction chemotherapy cisplatin-docetaxel patient NSCLC . Oral vinorelbine use present study rather intravenous form : 1- Previous investigation demonstrate oral vinorelbine effective intravenous form treatment NSCLC . 2 - We think use oral agent CT reduce disagreement provoke intravenous injection : stress , infection , hemorrhage , displacement hospital cost CT .</brief_summary>
	<brief_title>Oral Vinorelbine Cisplatin Concurrent Radiotherapy After Induction Chemotherapy Locally Advanced NSCLC .</brief_title>
	<detailed_description>About one-third patient non-small-cell lung cancer ( NSCLC ) inoperable , locally advanced stage III disease diagnosis . The satisfactory treatment patient locally advance NSCLC combination chemotherapy-radiotherapy ( CT-RT ) . However , optimal interval irradiation chemotherapy well effective chemotherapy protocol remain define . Our aim conduct multicenter phase II trial cisplatin-oral vinorelbine -radiotherapy combination induction chemotherapy cisplatin-docetaxel patient NSCLC . Oral vinorelbine use present study rather intravenous form : 1- Previous investigation demonstrate oral vinorelbine effective intravenous form treatment NSCLC . 2 - We think use oral agent CT reduce disagreement provoke intravenous injection : stress , infection , hemorrhage , displacement hospital cost CT . Patients enrol study member GFPC , French cooperative group thoracic oncology . The main eligibility criterion : histologically cytologically document inoperable stage IIIA N2 IIIB NSCLC previously untreated , absence malignant pleural effusion , performance status ( PS ) =1 patient life expectancy least 12 week . Induction chemotherapy comprise two cycle cisplatin 80mg/m2 docetaxel 75mg/m2 ( give D1 D22 ) . Concomitant CT-RT start D57 . Radiotherapy occur D57 D99 ( 2 Gy/day , 5 days/week , total dose 66 Gy ) . Cisplatin 80mg/m2 give D57 ( first day irradiation ) D78 . Oral vinorelbine 40 mg/m2 administer D57 , D64 , D78 D85 . The main endpoint objective response rate . The tumor response assess first end induction chemotherapy , 4 week concurrent CT-RT . Patients progress induction chemotherapy leave study . Those stable disease tumor response receive CT-RT combination . Tolerability , time progression , duration response proportion survival 1 , 2 3 year represent secondary endpoint . The study achieve accord French legislation guideline biomedical research involve human subject .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>histologically cytologically document inoperable stage IIIA N2 IIIB NSCLC previously untreated , absence malignant pleural effusion , performance status ( PS ) =1 patient life expectancy least 12 week . metastatic disease , small Cell lung carcinoma , prior chemotherapy , prior radiotherapy , resecable tumor , instable systemic disease , malignancy within 5 year ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Non-Small-Cell Lung , radiotherapy , Chemotherapy , vinorelbine</keyword>
</DOC>